No buy transactions available for this period
Enavate Sciences Gp, LLC filed its 13F report for Q2 2026 on August 14, 2026. The portfolio totaled 345.38 M reflecting a -1.74% change from the prior quarter, spanning 7 assets. The top 10 holdings comprised 100.0% of the portfolio, with Financials as the largest sector allocation. No significant position changes were reported during the quarter.
Items:
Total Value:
| Issuer Name | Class | Value | Shares | Option Type |
|---|
Enavate Sciences Gp submitted their Form 13F-HR for the Q2 2026 period on 08/14/2026. This was the only submission for the quarter.
In the Q2 2026 filing, Enavate Sciences Gp reported a managed portfolio value of 345.38 M, consisting of 7 individual positions.
This page displays the raw filing documents. To see which stocks Enavate Sciences Gp bought or sold during Q2 2026, please visit Enavate Sciences Gp's Portfolio Analysis page.